Sponsor or institution
Clinical trials and research at Peking University Cancer Hospital & Institute
As of November 12, 2026, Find a Trial lists 55 clinical trials run by Peking University Cancer Hospital & Institute that are recruiting, in China. By phase: Phase 2 (19), Phase 1 (5), Early Phase 1 (3), Phase 1/2 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 55Clinical trials
- 1Country
Newest trials
All recruiting trials (55)
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Local methylene blue injection around the pelvis to help avoid leakage after rectal cancer surgery
This study tests whether injecting a diluted methylene blue around the pelvic area after rectal cancer surgery can reduce leakage and help avoid a permanent stoma in high-risk patients.
-
18F-grazy-02 PET/CT to monitor immune therapy in cancer
This study tests whether 18F-grazy-02 PET/CT can safely monitor immune therapy in people with lymphoma or solid tumors being treated with immune checkpoint inhibitors or CAR-T cells.
-
Firmonertinib given before surgery for EGFR-mutated NSCLC
This study tests whether taking firmonertinib before and around surgery helps patients with resectable EGFR-mutated NSCLC see more tumor shrinkage before the operation.
-
CAIX-targeted PET imaging to help diagnose kidney cancer
This early-phase PET imaging study tests a CAIX-targeted tracer to see if it can help identify clear cell renal cell carcinoma in patients with kidney cancer.
-
Regorafenib plus envafolimab versus physician's choice for metastatic GIST with KIT exon 17 mutation
This study will test whether combining regorafenib with the immune drug envafolimab helps people with metastatic GIST who have KIT exon 17 mutations and have stopped responding to standard treatments.
-
89Zr-s-C1 PET/CT imaging to find MUC18-expressing solid tumors
This project will test whether a new PET/CT tracer, 89Zr-s-C1, can detect tumor lesions in people with solid tumors and reflect MUC18 expression.
-
Maintenance treatment with [225Ac]Ac-DOTATATE plus tislelizumab for extensive‑stage small cell lung cancer with somatostatin receptor–positive tumors
This trial will try to see if adding a targeted radioligand ([225Ac]Ac‑DOTATATE) to the immunotherapy drug tislelizumab as maintenance helps people with extensive‑stage small cell lung cancer whose tumors are somatostatin receptor positive after first‑line treatment.
-
Sacituzumab govitecan (Trop-2 ADC) for breast cancer that has spread to the brain
This real-world project will try sacituzumab govitecan (a Trop‑2 antibody–drug conjugate) in adults with breast cancer brain metastases to see if it improves control of brain tumors and how safe it is in routine care.
-
Perioperative albumin-bound paclitaxel plus SOX chemotherapy with sintilimab for HER2-negative hepatoid stomach cancer
This trial will try giving pre- and post-surgery chemo (albumin-bound paclitaxel and SOX) together with the immunotherapy drug sintilimab to people with locally advanced HER2-negative hepatoid stomach cancer to see if it shrinks tumors and improves outcomes.
-
Vebreltinib plus furmonertinib for EGFR‑TKI–resistant NSCLC with c‑MET amplification
This study tests whether giving vebreltinib together with furmonertinib can help people with advanced NSCLC that developed c‑MET amplification after their EGFR‑targeted therapy stopped working.
-
QL1706 plus celecoxib in advanced ESCC that progressed after prior immunotherapy
This study tests whether giving QL1706 with celecoxib can help people with advanced esophageal squamous cell carcinoma who stopped responding to prior immune therapy.
-
Trop‑2–targeted PET imaging for advanced triple‑negative breast cancer
This project will test whether a Trop‑2–targeted PET scan (89Zr‑DFO‑hSR7) can find Trop‑2–positive tumors and track response to sacituzumab govitecan in people with advanced triple‑negative breast cancer.
-
Dexamethasone, azacitidine, pegaspargase and tislelizumab with radiotherapy for stage I–II extranodal NK/T‑cell lymphoma
This treatment plan will test whether combining four drugs (dexamethasone, azacitidine, pegaspargase, and tislelizumab) with radiotherapy helps adults with stage I–II extranodal NK/T‑cell lymphoma.
-
Perioperative RC48 (Disitamab Vedotin) with sindillizumab and SOX for HER2‑expressing hepatoid stomach cancer
This trial tests whether giving Disitamab Vedotin (RC48) together with sindillizumab and SOX chemotherapy before and after surgery helps people with locally advanced HER2‑expressing hepatoid stomach cancer and is safe.
-
Combination therapy for advanced triple-negative breast cancer
This study is testing a new combination of two drugs to see if it can help people with advanced triple-negative breast cancer live longer and feel better.
-
Golidocitinib plus tislelizumab and chemotherapy for first-line advanced NSCLC
This phase 1 trial will try adding golidocitinib to tislelizumab and chemotherapy to see if people with advanced NSCLC and PD-L1 ≥1% can live longer without their cancer getting worse.
-
Evaluating neoadjuvant immunotherapy for lung cancer treatment outcomes
This study is trying to see if giving immunotherapy before surgery helps people with non-small cell lung cancer live longer and feel better.
-
Adaptive follow-up for early-stage NSCLC patients with no detectable MRD after surgery
This trial will test whether people with resected early-stage NSCLC who have two post-surgery ctDNA tests showing no detectable MRD can safely skip standard adjuvant therapy and be closely monitored instead.
-
Using PET imaging to evaluate HER2 expression in breast cancer patients after neoadjuvant therapy
This study is testing a special imaging technique to see if it can help doctors understand how well breast cancer patients are responding to treatment after they’ve received neoadjuvant therapy.
-
Chemoradiotherapy with NALIRIFOX for advanced rectal cancer
This study is testing a new treatment combining chemotherapy and radiation for people with advanced rectal cancer to see if it works better than the usual treatments.
-
Predicting response to immunotherapy in small cell lung cancer after chemotherapy and radiotherapy
This study is testing if a new maintenance therapy using a PD-L1 inhibitor can improve treatment outcomes for patients with limited-stage small cell lung cancer after they’ve had chemotherapy and radiotherapy.
-
Neoadjuvant camrelizumab plus chemotherapy to preserve the esophagus in resectable esophageal squamous carcinoma
This trial will test whether giving camrelizumab with nab-paclitaxel and cisplatin before surgery helps people with resectable esophageal squamous cancer preserve their esophagus and tolerate surgery.
-
Perioperative adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous carcinoma
We will test if giving adebrelimab with preoperative nab‑paclitaxel and cisplatin, followed by postoperative adebrelimab, helps people with resectable locally advanced esophageal squamous carcinoma.
-
Combining immunotherapy with targeted chemotherapy and radiotherapy for advanced lung cancer
This study is testing if combining immunotherapy with a specific type of chemotherapy and radiation can help people with advanced lung cancer live longer and feel better than standard treatments.
-
Adebelizumab with chemotherapy given with radiotherapy at the same time versus after radiotherapy for extensive-stage small cell lung cancer
This study tests whether adding adebelizumab to chemo and radiotherapy works better when given at the same time as radiotherapy compared to after radiotherapy in adults with extensive-stage SCLC.
-
Assessing the safety and efficacy of a new treatment for neuroendocrine tumors
This study is testing a new treatment for patients with advanced neuroendocrine tumors to see if it is safe and effective.
-
CD70-targeted CAR-NKT cell therapy for advanced solid tumors
This study is testing a new treatment using modified immune cells to see if it can help people with advanced solid tumors that have a specific marker called CD70.
-
MMP14-targeted PET imaging probe for solid tumors
Doctors are testing a 68Ga-labeled bicyclic peptide that can help visualize MMP14 expression in solid tumors using PET scans to see who might benefit from MMP14-targeted treatment.
-
Breast cancer: test a new imaging method to guide ADC drug therapy
This study tests whether PET/CT imaging with 68Ga-TTP can detect TROP2 expression in breast tumors and help monitor the effectiveness of an ADC drug treatment.
-
Modified Bufei Decoction to relieve post-surgery symptoms and support recovery for older lung cancer patients
This trial tests whether taking modified Bufei Tang granules twice daily for 28 days can reduce post-surgery cough, breathlessness, and fatigue in people aged 65 and older who had lung cancer surgery.
-
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
This study is testing a new imaging method using a special probe to see if it can help doctors better identify lung lesions in patients.
-
Using a special probe for PET imaging of solid tumors
This study is testing a new imaging method to see if it can help find specific solid tumors that have a marker called CD147, so that doctors can figure out who might benefit from targeted treatments.
-
Exploring biomarkers in patients with advanced colorectal cancer receiving combined immunotherapy and anti-angiogenic treatment
This study is testing if combining two types of immunotherapy with an anti-cancer treatment can help people with advanced colorectal cancer who haven't responded to other therapies.
-
Using PET imaging to predict treatment response in bladder cancer patients
This study is testing if a special imaging technique can help predict how well bladder cancer patients with certain tumors will respond to a new treatment.
-
Imaging solid tumors using a targeted radioactive probe
This study is testing a new radioactive probe to see if it can help improve PET imaging of solid tumors in patients by looking at how well it targets a specific protein found in those tumors.
-
Early diagnosis and treatment of gastric cancer using targeted imaging techniques
This study is testing a new way to find and treat gastric cancer earlier by using special imaging techniques and a targeted antibody that focuses on a specific protein in tumors.
-
Treatment for recurrent ovarian cancer with HER2 expression
This study is testing a new combination of treatments for women with recurrent ovarian cancer that has a specific protein called HER2 to see if it helps them feel better and live longer.
-
Combining immune and anti-angiogenic therapies for advanced liver cancer treatment
This study is testing three different combinations of immune and anti-cancer treatments to see which one works best for people with advanced liver cancer that can't be surgically removed.
-
Treatment of relapsed or refractory B-cell non-Hodgkin lymphoma with LUCAR-20SP
This study is testing a new CAR-T cell therapy called LUCAR-20SP to see if it can help adults with tough cases of relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Evaluating a new screening method for esophageal and gastric cancer
This study is trying out a new way to screen for esophageal and gastric cancer in people aged 50 to 69 in northern China to see if focusing on high-risk individuals improves detection rates.
-
Comparing total neoadjuvant treatment with and without immunotherapy for advanced rectal cancer
This study is testing whether adding an immunotherapy drug to standard treatment helps people with advanced rectal cancer respond better before surgery.
-
Evaluating immunotherapy with axitinib for advanced collecting duct carcinoma
This study is testing a new combination of immunotherapy and axitinib to see if it can help people with advanced collecting duct carcinoma who have already tried other treatments.
-
Organ preservation approach for low-risk rectal cancer
This study is testing if a less invasive treatment option can safely help patients with low-risk rectal cancer keep their organs after receiving a specific type of radiation and chemotherapy.
-
Niraparib maintenance therapy for advanced ovarian cancer after chemotherapy
This study is testing if a drug called niraparib can help women with advanced ovarian cancer stay healthy longer after they respond to chemotherapy.
-
Fluzoparib combined with camrelizumab and temozolomide for advanced melanoma
This study is testing a new combination of three drugs to see if it can help people with advanced melanoma that has certain genetic changes.
-
Combining radiation therapy with immunotherapy and targeted therapy for liver cancer
This study is testing whether combining a type of radiation therapy with two cancer drugs can help people with hard-to-treat liver cancer live longer without their disease getting worse.
-
Combining Camrelizumab, Apatinib, and Temozolomide for Advanced Acral Melanoma Treatment
This study is testing a new combination of three medications to see if it helps people with advanced acral melanoma live longer without their cancer getting worse compared to standard treatments.
-
Evaluating JCXH-212 alone and with Toripalimab for treating malignant solid tumors
This study is testing a new treatment called JCXH-212, both alone and with another drug called Toripalimab, to see if it can help people with advanced solid tumors that haven't responded to other treatments.
-
Using circulating tumor DNA to guide chemotherapy for colon cancer
This study tests if using blood samples to check for cancer DNA can help doctors decide how much chemotherapy colon cancer patients really need to improve their treatment outcomes.
-
Combination therapy for high-risk acral melanoma before surgery
This study is testing a new combination of treatments before surgery to see if it can help people with high-risk acral melanoma have better outcomes.
-
Using a special probe for PET imaging of solid tumors
This study is testing a new imaging method to see if a special probe can help find certain solid tumors in patients so they can get better-targeted treatments.
-
Imaging Nectin-4 in Bladder Cancer
This study is testing a new imaging method to see if it can help find a specific protein in patients with advanced bladder cancer to improve diagnosis and treatment planning.
-
Using Icotinib with chemotherapy before surgery for lung cancer patients
This study is testing if adding Icotinib to chemotherapy can help lung cancer patients with certain mutations feel better and have better surgery outcomes before their operation.
-
Combining Paclitaxel, Oxaliplatin, and S-1 for treating advanced gastric cancer
This study is testing a new combination of three drugs to see if it can help people with advanced stomach cancer become healthy enough for surgery.
Quick answers
How many clinical trials run by Peking University Cancer Hospital & Institute are recruiting right now?
55, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 19, Phase 1: 5, Early Phase 1: 3, Phase 1/2: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.